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Abstract
Background: Personalized drug prescription can be benefited from the use of intelligent information management
and sharing. International standard classifications and terminologies have been developed in order to provide unique
and unambiguous information representation. Such standards can be used as the basis of automated decision
support systems for providing drug-drug and drug-disease interaction discovery. Additionally, Semantic Web
technologies have been proposed in earlier works, in order to support such systems.
Results: The paper presents Panacea, a semantic framework capable of offering drug-drug and drug-diseases
interaction discovery. For enabling this kind of service, medical information and terminology had to be translated to
ontological terms and be appropriately coupled with medical knowledge of the field. International standard
classifications and terminologies, provide the backbone of the common representation of medical data while the
medical knowledge of drug interactions is represented by a rule base which makes use of the aforementioned
standards. Representation is based on a lightweight ontology. A layered reasoning approach is implemented where at
the first layer ontological inference is used in order to discover underlying knowledge, while at the second layer a
two-step rule selection strategy is followed resulting in a computationally efficient reasoning approach. Details of the
system architecture are presented while also giving an outline of the difficulties that had to be overcome.
Conclusions: Panacea is evaluated both in terms of quality of recommendations against real clinical data and
performance. The quality recommendation gave useful insights regarding requirements for real world deployment
and revealed several parameters that affected the recommendation results. Performance-wise, Panacea is compared
to a previous published work by the authors, a service for drug recommendations named GalenOWL, and presents
their differences in modeling and approach to the problem, while also pinpointing the advantages of Panacea.
Overall, the paper presents a framework for providing an efficient drug recommendations service where Semantic
Web technologies are coupled with traditional business rule engines.
Keywords: Ontologies, Decision support, Rule-based reasoning, Drug recommendations
Background
One of the health sectors where intelligent information
management and information sharing compose valuable
preconditions for the delivery of top quality services is
personalized drug prescription. This is more evident in
cases where more than one drug is required to be pre-
scribed, a situation which is not uncommon, as drug inter-
actions may appear. The problem is magnified by the wide
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range of available drug substances in combinationwith the
various excipients in which the former are present.
If one takes into account that there exist more than
18,000 pharmaceutical substances, including their excip-
ients, then it is clear that the continuous update of
health care professionals is remarkably hard. Over this,
the extensive literature makes discovery of relevant infor-
mation a time consuming and difficult process, while the
different terminologies that appear between sources add
more burden on the efforts of medical professionals to
study available information.
Semantic Web technologies can play an important role
in the structural organization of the available medical
information in a manner which will enable efficient
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discovery and access. Research projects funded for
enabling Semantic Web technologies in the diagnosis and
therapeutic procedures exist such as REMINE [1], PSIP
[2], NeOn [3] and Active Semantic Documents [4] or
works such as [5], but they don’t fully address the prob-
lem of automated drug prescription using drug-drug and
drug-disease interactions.
Rule-based approaches have been proposed for address-
ing issues relating to biomedical ontologies research. It
is common for ontologies written in expressive Seman-
tic Web languages such as OWLa, to not be able to
handle all requirements for capturing the knowledge in
several biomedical and medicine domains. As a method
for enriching the expressiveness of ontology languages,
researchers have proposed the use of rules which act upon
the defined ontological knowledge. According to [6], rules
are helpful in the following situations relating to biomed-
ical ontologies: defining “standard rules” for chaining
ontology properties, “bridging rules” for reasoning across
different domains, “mapping rules” for defining map-
pings between ontologies entities and “querying rules” for
expressing complex queries upon ontologies. The author
gives a thorough review of RuleMLb and SWRLc, the two
major ontology rule languages, the available rule forma-
tion tools and the reasoners. Golbreich et al. [7] makes
use of the outcomes of the previous paper to showcase
the need for rules in biomedical applications with a use
case of a brain anatomy definition, where a brain struc-
ture ontology is defined in OWL but rules describing the
relationships between the properties and entities that are
needed for correct annotation of MRI images. Another
work citing the need for semantically enriched rules,
where an ontology is coupled with SWRL rules for anno-
tating pseudogenes and answering research questions, has
been proposed in [8]. All the above papers present the
need for extending ontologies with rules in order capture
the knowledge of complex biomedical domains.
The paper presents Panacea, a semantic-enabled sys-
tem for discovering drug recommendations and inter-
actions. Panacea is based on experiences and lessons
drawn from the development of GalenOWL [9], a sim-
ilar system which had Semantic Web technologies in
its core. As such, Panacea can be considered the evo-
lution of GalenOWL in terms of design and scalability.
Panacea makes use of established and standardized med-
ical terminologies together with a rich knowledge base
of drug-drug and drug-diseases interactions expressed as
rules. Panacea is implemented having in mind scalabil-
ity, completeness of results and responsiveness in query
answering.
Standard terminologies and semantic web
Standard terminologies and classifications in the med-
ical domain have been developed in order to support
information sharing and exchange and to enable a com-
mon expression of key concepts. Such is the case for
example for the ICD-10d (International Classification of
Diseases) index of theWorld Health Organization (WHO)
where “it is used to classify diseases and other health prob-
lems recorded on many types of health and vital records”
across many countries. The classification is also used for
storing and retrieval of diagnostic information and for
the compilation of national statistics reports by the WHO
members.
On the other hand, ontologies and the Semantic Web
enable a common representation and understanding of
knowledge. Ontologies can effectively capture a domain’s
knowledge by “specifying the definitions of terms by
describing their relationships with other terms”. A rea-
soner can be employed upon an ontology in order to
uncover implicitly defined information while the expres-
siveness of ontologies can be further enriched by formu-
lating rules in standard rule languages, such as RuleML
or SWRL that are mentioned above, thus not sacrificing
interoperability.
Panacea aims to combine and make use of the benefits
of standard terminologies and Semantic Web technolo-
gies by enabling inference and rule-based reasoning on
ontologies that have been expressed using the medical
standards.
Methods
Architecture and functional design
The purpose of Panacea is to provide drug prescription
recommendations based on a patient’s medical record, i.e.
advise physicians to prescribe medications according to
the drugs active substance indications and contraindica-
tions. For details regarding the initiative that triggered
development of Panacea and the initial medical and phar-
maceutical data that were available, the reader is encour-
aged to read [9].
Panacea follows a layered reasoning process which is
depicted in Figure 1. During the start-up of the system,
the medical terminologies, namely ATCe (Anatomical
Therapeutic Chemical), UNIIf (Unique Ingredient Identi-
fier), ICD-10, ICTVg (International Virus Taxonomy) and
custom encodings, are transformed to semantic entities,
using an appropriate vocabulary, and the initial ontol-
ogy is constructed. The ontology binds to a reasoner to
infer relations such as inheritance and unions. This pro-
cess is performed once offline during initialization and the
knowledge base is available to the system for further uti-
lization. In order to get recommendations in Panacea, a
patient instance with the appropriate medical record data
is created and fed to the knowledge base. The reasoning
process enriches the patient instance with inferred knowl-
edge, thus making it explicit. On this enriched instance,
and by utilizing a different reasoning process, the set of
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Figure 1 Panacea framework architecture and data flow.
medical rules is applied upon. The result of this final stage
of rule-based reasoning is the recommendations list which
can be retrieved through SPARQLh querying.
A key characteristic of the suggested architecture is
that, regarding second level reasoning, the framework can
utilize any rule-based reasoner or rule engine. Since all
the inferred knowledge of the medical definitions and
patient data is materialized in the knowledge base, the
medical rules can be expressed and loaded in an appro-
priate rule engine. The rule engine could be an ontology
reasoner or a business rule manager with appropriate cus-
tomizations in the data structures. This approach helps in
bringing together the best of both worlds: semantic and
meaningful representation of data using Semantic Web
technologies and the maturity of traditional rule engines
in efficiently handling complex and large amounts of
rules.
Use case scenario
In order to demonstrate the benefits of the proposed
semantic recommendation system, a use case regarding
a possible scenario is described below. The codings in
the parentheses represent the corresponding ICD-10 and
ATC codes of diseases and drugs, respectively.
An elder man visits his family doctor complaining
for pain in his right lower back and abdominal region
which is accompanied with fever. After appropriate clin-
ical examination, he is diagnosed with right pyelonephri-
tis (ICD-10: N11.0). According to the patient’s medical
history, he is suffering from chronic atrial fibrillation
(ICD-10: I48.2) for which he receives clopidogrel (ATC:
B01AC04), vertigo (ICD-10: H81.49) for which he receives
cinnarizine (ATC: N07CA02), high arterial blood pressure
(ICD-10: I10) for which he receives candesartan (ATC:
C09CA06) and amlodipine (ATC: C08CA01), and dia-
betes mellitus (ICD-10: E11.9) for which he receives met-
formin (ATC: A10BA02) and sitagliptin (ATC: A10BH01).
For the new condition of pyelonephritis that was diag-
nosed, the treating doctormust decide a number of things.
Regarding the prescription for treating this new disease,
the doctor has to decide which active substances to pre-
scribe in order to treat the resulting inflammation, the
cause of the inflammation, the back and abdominal pain
and the resulting fever.
However, before a decision is made the following fac-
tors regarding the patient’s medical history should also be
considered:
• There should be a check for drug-drug interaction
that the patient is taking, before the onset of the new
condition (the pyelonephritis).
• There should be a check for drug-disease interaction
of the drugs that the patient is already prescribed
with the new condition.
• The new prescription has to be verified that it will
not have adverse effects or interactions with the
previously prescribed medication and with the
patient’s medical history.
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It is clear that the task for the doctor can be hard and a
misjudgment could lead to wrong prescriptions. Using an
automated drug recommendation system can minimize
this risk. The recommendation system will use the input
data and the pharmaceutical rules in order to propose a
treatment that will be safe for the patient.
Semantic transformations
Panacea is built on top of international standards of
medical terminology in order to represent medical and
pharmaceutical information. The following standard ter-
minologies are used:
ICD-10: International Classification of Diseases. It is
used in Panacea for unique identification of diseases
thus uniquely identifying drug indications and
contraindications related to diseases. The latest 2010
version was used in this work.
UNII: Unique Ingredient Identifier. Used for the
identification of active ingredients found in drugs. In
Panacea it is used for uniquely identifying drug
indications and contraindications related to
ingredients. The 2013 index was used.
ATC: The Anatomical Therapeutic Chemical
Classification is used for the classification of drugs. In
Panacea it is used in similar fashion to UNII. The
latest 2013 index was used.
ICTV: The International Committee on Taxonomy
of Viruses indexing is used for the classification of
viruses. In Panacea it is used in order to uniquely
drug indications and contraindications related to
viruses. The latest 2012 release was used.
Besides these international standards, a number of
domain classifications have been declared and used in
order to enhance the usability of the system or to repre-
sent data that are not included in the standards. These
classifications act as supplementary to the standards.
Substance: As the use of encodings for drug ingre-
dients is not convenient for humans, the identification
of active substances is done using its common name
references in medical bibliography. These names come
from international standards such as the INN (Interna-
tional Nonproprietary Names) and others such as USAN
(United States Adopted Name) or BAN (British Approved
Name). Members of this identification list are substances
such as acetazolamide or isradipine. In addition, sub-
stances correspond to ATC codes such that for example
acetazolamide ≡ S01EC01. The substances are the actual
recommendations of Panacea.
Custom Concepts: While the ATC, ICD-10, UNII and
ICTV standards are complete, they are designed for use in
contexts different from Panacea and drug recommenda-
tions, e.g. for annotation, search or information retrieval.
As such, it is often desirable to enrich the knowledge base
with information that, while not standard, will aid in the
usability and overall efficiency of the system. Especially for
medical/pharmaceutical rules formulation, it was found
out that there were occasions that the definition of dis-
eases, drugs or other was either absent, incomplete or
too general to be useful for a rule definition. An exam-
ple for the lack of a definition in ICD-10 is the absence of
a precise and specific code for “Chronic obstructive pul-
monary disease” or for “Hypertrophy (benign) of prostate”
which is under the general code N40 - Hyperplasia of
prostate among other hyperplasia conditions. For this rea-
son, a number of custom concepts have been defined.
Examples of such concepts is disease definition such
as “Narcolepsy”, microorganisms such as “clostridium
clostridiiformis” or medical acts such as “upper extremity
arteriography”.
Custom Concept Collections: Certain “groups” of sub-
stances and/or diseases are frequently present in drug
interactions and these groups are not recorded explicitly
in any standardized classification, so it’s more convenient
for medical use to specify these custom groups. These
often used groups are termed “conditions” in Panacea and
are defined by medical experts. A condition can appear as
a premise in other condition definitions, as in the Custom
Concept Collection cardiac-rhythm-abnormalities:
cardiac-rhythm-abnormalities = cc:bradycardia |
icd:R00 | cc:tachycardia | icd:O68.0 | icd:O68.2 where
cc:bradycardia is defined as “icd:I49.5 | icd:R00.1 |
icd:O68.0” and cc:tachycardia as “icd:R00.0 | icd:I49.5 |
icd:I47 | icd:O68.0”. “icd:” stands for the ICD-10 names-
pace. 672 Custom Concept Collections have been defined
and are used in this work.
SKOS vocabulary
In the approach followed in [9], the medical standards and
the custom definitions were translated to OWL classes,
primitive and defined.While this approach had the benefit
of using the language’s semantics to model the avail-
able information, there were problems resulting from this
design decision. One of the major issues was the difficulty
in scaling the system. Until currently, very few reasoners
are available that can efficiently handle the amount of class
definitions and reasoning required to run the system, both
in terms of memory consumption and speed.
In Panacea, a different approach was adopted. The
SKOSi (Simple Knowledge Organization System) vocab-
ulary is a W3C (World Wide Web Consortium) recom-
mendation, it’s built using RDFS (Resource Description
Framework Schema) semantics and has been devel-
oped as a low-cost migration path for porting existing
knowledge organization systems, such as thesauri, tax-
onomies, classification schemes and subject heading sys-
tems, to the Semantic Web. It enables a “lightweight”
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semantic representation of such knowledge systems and
is a good match for the medical standards that are
used in Panacea. As such, all the terminologies which
are mentioned in the previous section have been trans-
formed using the SKOS vocabulary automatically using a
parser.
Comparing SKOS to the approach followed in [9],
instead of representing the ATC, ICD-10 and UNII classi-
fications as top-level classes, they are now represented as
instances of the skos:ConceptScheme class. “skos:” stands
for the SKOS namespace. Each entry in these classifica-
tions is represented as an instance of the skos:Concept
class. The OWL class hierarchy of [9] is represented
in Panacea using the properties skos:broaderTransitive
and skos:narrowerTransitive, while the unions of classes
for Custom Concepts Collections are represented using
the skos:member property. Correspondence between the
semantic transformation methodologies that were fol-
lowed in the current work and in [9] is presented in
Table 1.
It is interesting to note that the SKOS vocabulary offers
exactly what is needed in order to capture the semantics
of the medical classifications without making sacrifices in
expressiveness. One can argue that it can be considered
more precise than the OWL expressions, as in the case
of the similarity of Substances and ATC codes. This simi-
larity is better represented by the skos:closeMatch relation
than owl:equivalentClass. For Panacea a total of 64, 658
definitions of classification codes have been expressed
using SKOS.
Panacea ontology and reasoning
The core ontology of Panacea is visualized in Figure 2.
The aforementioned SKOS ontologies were imported to
the Panacea core ontology under the MedicalDefinitions
class. The Patient class holds the patient instances and
is connected to the MedicalDefinitions class with the
hasData properties. The patient recommendations, indi-
cations and contraindications, regarding substances that
should and should not be prescribed are expressed with
the canTake and cannotTake properties, respectively. The
patients age group and sex group are expressed through
the hasAgeGroup and hasSexGroup properties.
Table 1 Correspondence between the semantic





Custom collections owl:unionOf skos:member
Hierarchy rdfs:subClassOf skos:broaderTransitive
Figure 2 Panacea ontology.
Medical reasoning
When querying the system for recommendations, a
patient instance is created with the initial patient data
(through the hasData, hasAgeGroup and hasSexGroup
properties) and is loaded in the knowledge base. The
reasoner, using RDFS inference and a small number
of additional rules, infers all the implicit patient data.
As an example consider a patient who suffers from
a form of thrombocytopenia. An instance is created
with the property <pnc:patient pnc:hasData icd:D69.6>.
The reasoner through the skos:broaderTransitive relation
will infer the triples <pnc:patient pnc:hasData icd:D69>,
<pnc:patient pnc:hasData icd:D65-D69>, <pnc:patient
pnc:hasData icd:D50-D89 >. Additionally, the custom col-
lection definition of pnc-cc:deficiency-bone-marrow has
icd:D69.6 as one of its members so the triplet <pnc:patient
pnc:hasData pnc- cc:deficiency-bone-marrow>will also be
inferred. At the end, the patient instance will be enriched
with all the underlying implicit information.
Rule-based reasoning
Drug recommendations in Panacea are generated using
a rule-based approach. The rules express the indica-
tions and contraindications of drug substances while their
premises are the medical definitions and the patients’ age
and sex group. The rules use the logical operators and (&)
and or (|) and parentheses. An example of a rule is for the
substance “ lisuride” which is expressed as
lisuride = icd:E22.0 | (icd:E22.1 & (icd:N91.0 | icd:N97)),
ageGroup=adult or elder
The above rule reads that the substance “lisuride” is
recommended for adult and elder patients who suffer
from E22.0, OR suffer from E22.1 AND one of the N91.0
OR N97. For using these rules, they have to be properly
parsed and transformed in order to match the knowledge
base and the enriched, with implicit knowledge, patient
instance. The proposed rule structure allows modifica-
tions to specific rules without the changes affecting the
rest of the rule base. This enables the rule base to be
up-to-date with the latest clinical advancements, which
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is a requirement as clinical pharmacology and medicine
are constantly evolving. Analyzing Panacea’s architec-
ture in Figure 1 it can be seen that due to the layered
reasoning approach, the knowledge base (medical defi-
nitions + reasoner) is actually used for producing the
enriched patient instance. This means that the instance
can be fed to a rule reasoner which has appropriately
loaded themedical-pharmaceutical rules, without the rea-
soner having to communicate with the knowledge base for
further utilization. Using this approach and with proper
modifications, any rule engine can be used to produce
the drug recommendations. To demonstrate this ability,
two separate rule engine integrations have been developed
and are presented below. The medical rule base consists
of 1, 342 rules which were extracted and encoded directly
from official documents, such as Summary of Product
Characteristics (SPC) and Patient Information Leaflets
(PIL), regarding drug indications, contraindications, inter-
actions and dosage. The validity of the rule base has
already been assessed in [9].
It should be noted that work is under way in order to add
more functionalities in the drug proposed recommenda-
tion system. One of these is the ability to offer additional
information such as the proposed dosage for a recom-
mended substance. In order to accomplish such a task, the
pharmaceutical rules are being enriched with clinical vari-
ables, other than sex and age group, that are important.
These variables include somatometric characteristics such
as height and body weight, creatinin clearance (useful for
calculating the dosage for antineoplasmic drugs) and the
disease itself as a substance could be indicated at a specific
dosage to treat a certain disease, but a different dosage is
recommended for another disease.
Jena rule engine
For using the rule engine of the Apache Jena APIj the rules
had to be translated to the Jena rule language. An auto-
mated parser was developed for this purpose. As for most
semantic rule reasoners, OR clauses are not allowed in a
rule definition so separate rules had to be expressed for
every premise that was OR’ed in the original rule base.










This rule expansion resulted in a total of 6, 451 rules
to be expressed in the Jena language. Trying to load the
whole rule base and performing inference for recommen-
dations proved inefficient for real time use, requiring on
average as much as 8 seconds. In order to tackle this issue
a coarse rule selection phase was introduced. The selec-
tion was executed in 2 iterations. During the first iteration,
a subset A of candidate rules is created from the initial
rule base, that match the patient’s sex and age group. This
subset is selected for further processing. In the second
iteration, rules from A that contain at least one of the
patient’s data, i.e. a skos term, in their premises are sin-
gled out and a final set R ⊆ A is created from them.
Remembering that the implicit knowledge extraction was
performed during the introduction of the patient instance
to the reasoning framework, creation of R is actually a
simple and fast process. It merely requires string match-
ing and all the whole processing is executed in memory.
As a result the overall burden that is added to the whole
reasoning process is minimal. From the initial rule base
of 6, 451 rules it is common for R to contain as less as
50 rules, whose evaluation is much more efficient. Rule
execution is performed with the Jena rule engine and the
patient instance is modified and now contains the drug
recommendations. These recommendations are retrieved
through SPARQL querying, using Jena’s query engine. The
advantage of the Jena engine is that it can readily consume
the patient instance for producing the recommendations.
Drools rule engine
As an alternative approach, the Droolsk business rule
engine was used. In contrary to Jena, Drools could not
directly use the patient instance for performing reason-
ing. For this purpose, the instance was transformed to a
Java bean, where the properties of the ontology Patient
class are mapped to Java methods using the JenaBean
APIl. A similar approach for integrating Jena and Drools
was used in [10]. The Drools rule language permits the
use of OR’ed clauses in the body, so the 1, 342 original
medical rules were translated to the same amount of
rules in Drools, using an automated parser similar to the
one used in the Jena approach. For example, the rule for
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Execution was straightforward with no preprocessing
required. Drools is optimized for handling large rule
bases, so no rule pre-selection step was required as this
would have little impact in reasoning efficiency. The result
of this reasoning process is a modified patient Java bean
with the drug recommendations. The Java bean is trans-
formed to Jena model instance and SPARQL querying
for retrieving the recommendations is possible. What this
approach demonstrates is that it’s possible to integrate
business rule engines as reasoners in the framework, thus
being able tomake use of the high efficiency and optimiza-
tions of these engines with the semantic description and
interpretation of data.
Evaluation and discussion
The evaluation of Panacea was performed using two dif-
ferent approaches. One approach assesses the quality of
drug recommendations while the other assesses the effi-
ciency of the developed system in terms of computational
requirements and performance which are of importance
when a system is launched in a production environment.
Both approaches are detailed in the next Sections.
Quality evaluation
The first approach involved the evaluation regarding real
clinical data from treated patients in a hospital environ-
ment. 21 anonymized patient medical record files (cases)
from the AHEPAm University Hospital of Thessaloniki
were gathered and an analysis was performed on then.
Data regarding the patients medical history (medication
that the patients are taking and active diseases that they
suffer from), diagnosis related to condition that lead the
patients visiting the hospital and the medication that was
actually prescribed, were gathered. These data formed the
basis against which the prescription recommendations,
that Panacea generates, were compared to. In addition,
all patient data (existing diseases, current medication,
newly diagnosed disease(s), newmedication) were used by
Panacea in order to discover possible interaction and/or
contra-indications that were either missed or disregarded
by the treating physicians. As such, the comparison iden-
tified the following:
• Average number of identified drug-drug interactions
per case
• Average number of identified drug-drug
contraindications per case
• Average number of identified drug-disease
interactions per case
• Average number of identified drug-disease
contraindications per case
• Percentage of agreement between the automatically
generated drug recommendations vs actual
prescription for all cases, i.e. how many of the
recommendations Panacea generated agreed with the
prescribed drugs, for the newly diagnosed disease(s).
Although it doesn’t affect the final results, it should be
noted that the evaluation took place using Drools as a
rule engine. The identified interactions and contraindica-
tions per case are displayed in Table 2. For most of the
cases where contraindicated drugs were prescribed, it was
either done deliberately, e.g. a patient suffering from brain
ischemia was administered tinzaparin and acetylsalicylic
acid for their (normally contraindicated) enhanced blood
thinning effect when combined, or because the con-
traindications were deemed unimportant related to the
patient’s critical condition. However there were a few
cases where the administration of contraindicated drugs
couldn’t be justified. For these cases we can assume that
the physicians didn’t have knowledge or made an error
during prescription. The use of an automated recom-
mendation system, such as the one presented, could have
prevented such errors.
At the next stage of the evaluation, the patients’ med-
ical history (active diseases and current medication) and
the current diagnosis was taken into account in order
to generate automatic recommendations from Panacea.
These recommendations were compared to the prescrip-
tion that the patients received from the hospital. Using
this comparison, Panacea managed to match the 67.1% of
the prescribed drugs (Table 3). While a level close to 100%
would have been expected in a fully controlled environ-
ment where all prescriptions are given according to formal
Table 2 Discovery of drug interactions and contraindications against real clinical data
Drug-drug Drug-drug Drug-disease Drug-disease
interactions/case contraind./case interactions/case contraind./case
3.28 0.43 4.48 0.24
Actual prescribed 7.38
drugs/case
0All numbers are average.
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Table 3 Matching recommendations




medical guidelines, this was not achieved due to several
parameters that their role was revealed during the eval-
uation. On average, Panacea recommended 62 different
drugs per case.
Several reasons that affected the recommendation
results have been identified. One of them is that in its
current form, Panacea rules expressing drug interactions
are binary, thus an interaction either exists or not with-
out having the means to express its level of effect (how
important it is considered). The presence of an interac-
tion, as unimportant as it may be, will exclude a relevant
active substance from recommendation while in princi-
ple the benefit of administering the substance might be
more important than a possible side effect. An example
in the current evaluation dataset is the administration of
the substance Budesonide to a patient whose current med-
ication contains Acetylsalicylic acid and has been newly
diagnosed with “Pneumonia”. The treating physicianmade
the decision that the benefit from receiving the Budes-
onide was greater that the risk of possible interactions.
Experienced physicians are in a position to effectively
make this kind of judgments.
Secondly, there is the possibility that patient data might
have been logged inaccurately, e.g. a patient was suffering
from Sepsis due to Staphylococcus aureus (ICD-10: A41.0)
while Sepsis (ICD-10: A41) was registered as diagnosis,
or some information from the diagnosis is missing, e.g.
a patient was diagnosed with “Pneumonia”, but the caus-
ing bacteria strand (staphylococcus) was omitted. Such
inaccuracies or missing information affect the automated
recommendations results as the recommendation rules
have to match all premises in order to produce the results.
An additional cause for decreased accuracy has been
mentioned earlier in the Section, i.e. contraindicated
drugs could be prescribed because they would cause a
desirable side effect that will be of benefit to the patient
as is the case of simultaneous delivery of tinzaparin and
acetylsalicylic acid in a patient with ischemic stroke. Espe-
cially for these situations, the experience of the treating
physician plays an important role for such decisions.
Panacea is the analogy of an inexperienced physician who
goes “by the book” in contrast to an experienced physician
who has the knowledge to make a successful compromise
between possible risks (from interactions) and benefits
(from the drug).
The above evaluation gave useful insights on ways where
Panacea could be improved in order to be a valuable tool
in a physician’s arsenal. Panacea has proven quite effective
in identifying drug interactions and contraindications.
Regarding the potential for actual drug recommendation,
although Panacea managed to propose various possible
treating drugs according to medical record data, these
recommendations in some cases varied from the actual
drug prescription that the patients received. Several fac-
tors that influenced the results have been identified. One
major issue seems to be that in many cases the diagnosis
is given in a general and unclear statement, e.g. respira-
tory infections or sepsis, while recommendation rules are
concretely structured and give answers to specific disease
diagnosis. For such recommendation systems to be effi-
cient, diagnosis as general as e.g. “respiratory infection”
are not adequate. The respiratory system starts from the
nostrils and ends in the pulmonary alveoli and there are
numerous ICD-10 codes that describe every individual
infection in the respiratory system, as there are numer-
ous bacteria or viruses that causes these infections. These
combinations of diseases and causes are precisely encoded
in Panacea’s rules and a precise diagnosis would generate
the exact recommendation. However, a treating physician
is often not in a position to exactly know the topology
and the cause of an infection so it is common to pre-
scribe drugs that cover most of the possible combinations.
This generalization of something specific, e.g. pneumo-
nia due to streptococcus, to something more general, e.g.
respiratory infection, is what affects the recommenda-
tions results. Issues such as the above should be taken
under consideration during the future development of
Panacea.
Performance evaluation
For evaluating the framework in terms of performance,
a comparison was made between the two approaches for
the final stage reasoning and with GalenOWL (with values
taken from [9]). The comparisons were focused on the
usability of the framework in a production environment
as the rule base has been validated in [9]. Three param-
eters were measured. These were initialization time, the
time to get the system up and running, memory consump-
tion after initialization, and query response time, i.e. the
time that is needed to have the rule base executed and the
results retrieved. Results are shown in Table 4.
There are some points to discuss in the table results.
Initialization involves loading the ontology in memory,
performing inference, and preparing the medical rule base
for patient data reasoning. In the Jena implementation, the
rule base is processed and loaded only after the patient
instance has been introduced to the system, while the
Drools implementation loads the whole rule base on the
engine before any patient data are introduced. As a result,
Drools appears slower than the Jena approach regarding
initialization. For the same reason, memory consumption
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Table 4 Evaluation between the 2 Panacea reasoning
approaches and GalenOWL
Panacea-Jena Panacea-Drools GalenOWL
Initialization 32.0 s 34.7 s 148 s
time
Memory 169 MB 280 MB 649 MB
consumption
of which rule base 0 MB 111 MB —
consumes
Query response 47 ms 5 ms 16 ms
time
appears greater for Drools. This metric corresponds to
memory consumption from initialization to recommen-
dations retrieval. While in Drools the whole rule base is
loaded on memory, in Jena the approach was to load a
small subset of the rule base that could possibly match the
patient data, which leads to a smaller memory footprint.
Finally, for query response the advantage is with Drools,
as was expected, mainly due to the fact that Drools is a
dedicated rule engine while Jena’s focus is not at providing
a state of the art reasoner and rule engine, but a versatile
API for ontology management.
Numerically, the Jena approach seems to be more effi-
cient than Drools, apart from the query execution time
but for which the difference is not important. How-
ever, while for the present knowledge base Jena seems
to perform better, this fact could change as more and
more rules are added. It is estimated that eventually at
its final stage, Panacea will incorporate more than 9, 000
drug-drug and drug-disease interactions. As already said,
Jena is more focused as an ontology API and less as an
efficient rule engine which could eventually lead to scal-
ing problems. On the other hand, scaling with Drools
is not an issue. The value of business rule engines as
Semantic Web reasoners has been previously exploited
using approaches such as [11], where the authors imple-
mented two OWL2-RL [12] reasoners using the Drools
and Jess rule engines respectively. The use of traditional
rule engines with the Semantic Web technologies brings
together the best of both worlds, i.e. increased efficiency
coupled with interoperability and semantic annotation of
information.
What is also noticeable from Table 4 is the decreased
memory requirement of Panacea compared to the pre-
vious OWL-based GalenOWL system, although the two
approaches offer very similar functionality. As a result of
this achievement, Panacea can accommodate a far greater
knowledge base thus supporting the claim of increased
scalability.
Panacea will eventually be offered as a service with
potential customers being health care professionals.
Other possible exploitation routes are being investigated
such as integration to patient management systems in
health clinics. The use of personalized drug prescription
systems, as Panacea, in everyday practice will have advan-
tages to the society and the economy. A major benefit
from the use of such systems is the reduction of medical
costs through rational drug prescriptions that personal-
ized drug prescription allows [13]. Another benefit is a
positive effect in public health with reduction of outbreaks
relating to drug interactions or adverse effects [14]. All
knowledge regarding drug information is encoded and
is available to the experts in order to aid them during
prescriptions thus acting as decision support systems. It
should be stressed out that drug recommendation systems
do not aim to replace medical experts but to support them
in their practice.
A limitation of the proposed approach is that a rather
large amount of manual effort by experts is required in
order to populate and enrich the rule base. Although the
semantic technologies that have been employed can make
rule authoring simpler, no automated method for phar-
maceutical rule generation has been integrated. However,
one would argue that since rule authoring is performed
by experts then the rules are verified and guaranteed to
be correct. Even if an automated method, such as rule
mining, had been implemented, the generated rules would
still have to be verified be an expert in the field. Man-
ual verification, although less intensive, would still be
required.
Conclusions
The paper presented Panacea, a framework for semantic-
enabled drug recommendations discovery. The frame-
work utilizes a layered reasoning approach were the
medical ontology and the patient data instances are fed
to an extended RDFS reasoner in order to infer implicit
knowledge. Drug recommendations are generated using
the second reasoning layer where any common rule engine
can be used. As a proof of concept implementation, the
Jena reasoner and the Drools rule engine has been inte-
grated. Two different evaluations were conducted. One
performance evaluation regarding requirements and effi-
ciency of the proposed approach, and a quality evaluation
regarding the system’s outcome in terms of real clinical
data. The quality evaluation gave insights regarding pos-
sible extensions that could make the system more in line
with current clinical practice. Future work on Panacea
will focus on providing ways to address the issues uncov-
ered during the quality evaluation and provide results
that more closely match a physician’s decision. These
could include improvements such as the weighting of
interactions and contraindications according to a sever-
ity observation and probabilistic inference based on these
weights. To this end, Drools is being extended with a fuzzy
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reasoning engine [15], which while it’s still in develop-
ment, it’s actively supported and it is mature enough to
be able to use it as a testing framework. Finally, the addi-
tion of dosage recommendations in the rules is an ongoing
work.
Endnotes
aOWL - Web Ontology Language, http://www.w3.org/
TR/owl2-overview/
bRuleML - Rule Markup Language, http://www.ruleml.
org
cSWRL - Semantic Web Rule Language, http://www.
w3.org/Submission/SWRL/
dICD-10 - International Classification of Diseases,
http://www.who.int/classifications/icd/en/
eATC - Anatomical Therapeutic Chemical
classification, http://www.whocc.no/atc/structure_and_
principles/
fUNII - Unique Ingredient Identifier, http://www.fda.gov/
ForIndustry/DataStandards/SubstanceRegistrationSystem-
UniqueIngredientIdentifierUNII/default.htm
gICTV - International Virus Taxonomy, http://www.
ictvonline.org/virusTaxonomy.asp
hSPARQL - Query language for RDF, http://www.w3.
org/TR/rdf-sparql-query/
iSKOS - Simple Knowledge Organization System,
http://www.w3.org/2009/08/skos-reference/skos.html
jApache Jena - Semantic Web framework, http://jena.
apache.org/
kDrools - Business logic integration platform, http://
www.jboss.org/drools
lJenaBean API, http://code.google.com/p/jenabean/
mAHEPA University Hospital of Thessaloniki, http://
www.ahepahosp.gr
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